For Treatment Centers
See the nervous system — before the relapse happens.
Revago gives PHP/IOP and residential SUD programs objective autonomic data on every client. Stress response profiling, craving-trajectory monitoring, medication-aware interpretation, and CPT-reimbursable biofeedback — built for the realities of addiction treatment.
0%
Reduction in substance use days vs. control in Phase 2 SUD RCT
Eddie et al., JAMA Psychiatry 2025
g = 0.00
Effect size for anxiety and stress across 24 RCTs
Goessl et al., 2017
0
Adults with SUD in the Phase 2 trial that demonstrated craving-to-use disruption
Eddie et al., 2025
0×
Larger effect from personalized vs. universal interventions
Stratton et al., 2025
Treatment Programs Are Flying Blind on Relapse Risk
40–60%
Relapse rate within one year of completing SUD treatment — comparable to other chronic illnesses
McLellan et al., JAMA, 2000
Self-report
Most programs rely on self-reported craving and mood — clients minimize, mask, or under-report
Field standard
Day-of
Autonomic destabilization typically precedes craving and use by hours to days — not minutes
Sinha & Li, 2007 (HPA stress reactivity)
By the time the client tells you something is wrong, the nervous system has been telling you for days. Revago surfaces those signals — and gives the clinical team something to do about them.
How Revago Works in a Treatment Program
Autonomic Phenotype
Every client completes a standardized autonomic stress test on admission. Revago classifies their phenotype, accounts for medications (naltrexone, buprenorphine, antidepressants), and matches them to a regulation protocol.
In-Program Biofeedback
Manualized HRV biofeedback sessions through the program — CPT 90875/90876 supported documentation. Live RMSSD, breathing pacer matched to the client's resonance frequency, session completion score on every session.
Trajectory Monitoring
Daily check-ins capture craving, mood, and brief autonomic readings. The clinical dashboard surfaces destabilization trends before they escalate to relapse.
The Research
Peer-Reviewed Evidence in SUD
HRV biofeedback is one of the most replicated non-pharmacological interventions in addiction medicine — and it's now being shown to disrupt the moment-level craving-to-use pathway.
Built For Real Treatment Settings
Residential & Detox
- •Autonomic profiling on admission — even mid-withdrawal
- •Medication-aware interpretation (buprenorphine, naltrexone, antidepressants)
- •Track autonomic recovery across stay
PHP / IOP
- •Group and individual biofeedback sessions
- •CPT 90875/90876 documentation built into the workflow
- •Family/support-person education portal
Outpatient & Aftercare
- •Continued autonomic monitoring after discharge
- •Early-warning alerts to the treatment team
- •Sustained self-regulation practice with progress data
MAT Programs
- •Autonomic phenotype as adjunct to MAT decision-making
- •Track autonomic shift across medication titration
- •Objective data alongside subjective craving scales
Not Another Mood-Tracker. Not Another Wearable.
Generic Recovery Apps
- Subjective self-report only
- No autonomic measurement
- No clinician workflow
- One-size-fits-all content
- No phenotype or medication awareness
- No fidelity scoring
Revago
- Objective autonomic measurement on every encounter
- Phenotype-matched intervention prescription
- Manualized clinical workflow with CPT-supported documentation
- Medication-aware interpretation (MAT, antidepressants, antipsychotics)
- Live RMSSD and resonance-frequency biofeedback in session
- Per-session session completion score for supervision and audit
The Clinical & Business Case
64%
Reduction in substance use days vs. control in a Phase 2 RCT of 115 adults with SUD.
Eddie et al., JAMA Psychiatry, 2025
OR = 0.36
Odds of substance use following a craving episode — HRV biofeedback disrupted the moment-level craving-to-use pathway.
Eddie et al., 2025
CPT 90875 / 90876
Biofeedback codes supported by Revago documentation — pathway to reimbursable in-program billing.
AMA CPT, current edition
Better autonomic data means earlier intervention, fewer destabilizations, and a defensible billing pathway your program can actually use.
Program Deployment Options
Option A
Single-Site Pilot
One detox, PHP/IOP, or residential site, Revago-trained clinicians, 90-day outcomes evaluation. Includes onboarding and supervision support.
Best for: Detox and treatment programs evaluating measurement-based care for the first time
Option B
Multi-Site System License
System-wide licensing with shared dashboard across sites, central supervision visibility, and benchmarking across programs.
Best for: Health systems and multi-site treatment networks
Option C
Research-Forward Partnership
Implementation paired with structured outcomes research. Co-author real-world effectiveness data with our scientific team.
Best for: Programs with research interest or academic affiliations
Get in Touch
Bring Objective Autonomic Data Into Your Program
Tell us about your treatment center and we'll set up a clinical walk-through with your program's medical director and clinical lead.